Explore

Trendline Trendline
ADC Therapeutics Faces Share Price Drop After Zynlonta Trial Deaths

ADC Therapeutics Faces Share Price Drop After Zynlonta Trial Deaths

ADC Therapeutics Faces Share Price Drop After Zynlonta Trial Deaths
Trendline Trendline
ADC Therapeutics Faces Share Price Drop After Patient Deaths in Zynlonta Trial

ADC Therapeutics Faces Share Price Drop After Patient Deaths in Zynlonta Trial

ADC Therapeutics Faces Share Price Drop After Patient Deaths in Zynlonta Trial
Trendline Trendline
Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial

Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial

Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial
Trendline Trendline
Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine

Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine

Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine
Trendline Trendline
ADC Therapeutics Faces Setback as Lymphoma Drug Trial Results in 27 Deaths

ADC Therapeutics Faces Setback as Lymphoma Drug Trial Results in 27 Deaths

ADC Therapeutics Faces Setback as Lymphoma Drug Trial Results in 27 Deaths
Trendline Trendline
Eli Lilly and Ascidian Therapeutics Partner on $1.9 Billion RNA Exon Editing for Kidney Diseases

Eli Lilly and Ascidian Therapeutics Partner on $1.9 Billion RNA Exon Editing for Kidney Diseases

Eli Lilly and Ascidian Therapeutics Partner on $1.9 Billion RNA Exon Editing for Kidney Diseases
Trendline Trendline
Eli Lilly Partners with Ascidian Therapeutics in $1.9 Billion Deal for Kidney Disease Treatment

Eli Lilly Partners with Ascidian Therapeutics in $1.9 Billion Deal for Kidney Disease Treatment

Eli Lilly Partners with Ascidian Therapeutics in $1.9 Billion Deal for Kidney Disease Treatment
Trendline Trendline
Eli Lilly Partners with Ascidian for $1.9 Billion Kidney Disease RNA-Editing Collaboration

Eli Lilly Partners with Ascidian for $1.9 Billion Kidney Disease RNA-Editing Collaboration

Eli Lilly Partners with Ascidian for $1.9 Billion Kidney Disease RNA-Editing Collaboration
Trendline Trendline
ADC Therapeutics Faces Setback as Patient Deaths Impact Zynlonta Trial

ADC Therapeutics Faces Setback as Patient Deaths Impact Zynlonta Trial

ADC Therapeutics Faces Setback as Patient Deaths Impact Zynlonta Trial
Trendline Trendline
ASCO 2026 Highlights Breakthroughs in Cancer Treatment Innovations

ASCO 2026 Highlights Breakthroughs in Cancer Treatment Innovations

ASCO 2026 Highlights Breakthroughs in Cancer Treatment Innovations
Trendline Trendline
IDEAYA and Roche Partner to Test New Pancreatic Cancer Treatment

IDEAYA and Roche Partner to Test New Pancreatic Cancer Treatment

IDEAYA and Roche Partner to Test New Pancreatic Cancer Treatment
Trendline Trendline
Eli Lilly Partners with Ascidian for RNA Exon Editing in Kidney Disease

Eli Lilly Partners with Ascidian for RNA Exon Editing in Kidney Disease

Eli Lilly Partners with Ascidian for RNA Exon Editing in Kidney Disease